A pilot study on the preventative potential of alpha-cyclodextrin and hydroxytyrosol against SARS-CoV-2 transmission.
Adult
Antiviral Agents
/ therapeutic use
Betacoronavirus
COVID-19
Coronavirus Infections
/ diagnosis
Cyprus
Endocytosis
/ drug effects
Female
Humans
Male
Middle Aged
Oral Sprays
Pandemics
/ prevention & control
Phenylethyl Alcohol
/ analogs & derivatives
Pilot Projects
Pneumonia, Viral
/ diagnosis
SARS-CoV-2
Viral Load
alpha-Cyclodextrins
/ therapeutic use
COVID-19 Drug Treatment
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
09 11 2020
09 11 2020
Historique:
received:
16
10
2020
accepted:
16
10
2020
entrez:
10
11
2020
pubmed:
11
11
2020
medline:
20
11
2020
Statut:
epublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current pandemics. This virus attacks the cells by binding to the transmembrane angiotensin I converting enzyme 2. In this study, we experimented a food supplement containing alpha-cyclodextrin and hydroxytyrosol for the improvement of the defenses against the SARS-CoV-2. Hydroxytyrosol has anti-viral properties and is able to reduce the serum lipids in mice. α-cyclodextrin has the ability to deplete sphingolipids and phospholipids from the cellular membranes. The aim of the present preliminary open non-controlled interventional study was to evaluate the efficacy of alpha-cyclodextrin and hydroxytyrosol in improving defenses against SARS-CoV-2. Fifty healthy volunteers at a higher risk of SARS-CoV-2 infection from Northern Cyprus and six positive individuals for SARS-CoV-2 were enrolled in this study. The in silico prediction was performed using D3DOCKING to evaluate the interactions of hydroxytyrosol and alpha-cyclodextrin with proteins involved in the SARS-CoV-2 endocytosis. The 50 volunteers did not become positive in 15 days for SARS-CoV-2 after the administration of the compound for two weeks, despite they were at higher risk of infection than the general population. Interestingly, in the cohort of six positive patients, two patients were administered the spray and became negative after five days, despite the viral load was higher in the treated subjects than the untreated patients who became negative after ten days. In addition, we identified possible interactions among hydroxytyrosol and alpha-cyclodextrin with the protein Spike and the human proteins ACE2 and TMPRSS2. We reported on the results of the possible role of alpha-cyclodextrin and hydroxytyrosol in improving defenses against SARS-CoV-2. The next step will be the administration of the compound to a larger cohort in a controlled study to confirm the reduction of the infection rate of SARS-CoV-2 in the treated subjects.
Sections du résumé
BACKGROUND AND AIM OF THE WORK
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current pandemics. This virus attacks the cells by binding to the transmembrane angiotensin I converting enzyme 2. In this study, we experimented a food supplement containing alpha-cyclodextrin and hydroxytyrosol for the improvement of the defenses against the SARS-CoV-2. Hydroxytyrosol has anti-viral properties and is able to reduce the serum lipids in mice. α-cyclodextrin has the ability to deplete sphingolipids and phospholipids from the cellular membranes. The aim of the present preliminary open non-controlled interventional study was to evaluate the efficacy of alpha-cyclodextrin and hydroxytyrosol in improving defenses against SARS-CoV-2.
METHODS
Fifty healthy volunteers at a higher risk of SARS-CoV-2 infection from Northern Cyprus and six positive individuals for SARS-CoV-2 were enrolled in this study. The in silico prediction was performed using D3DOCKING to evaluate the interactions of hydroxytyrosol and alpha-cyclodextrin with proteins involved in the SARS-CoV-2 endocytosis.
RESULTS
The 50 volunteers did not become positive in 15 days for SARS-CoV-2 after the administration of the compound for two weeks, despite they were at higher risk of infection than the general population. Interestingly, in the cohort of six positive patients, two patients were administered the spray and became negative after five days, despite the viral load was higher in the treated subjects than the untreated patients who became negative after ten days. In addition, we identified possible interactions among hydroxytyrosol and alpha-cyclodextrin with the protein Spike and the human proteins ACE2 and TMPRSS2.
CONCLUSIONS
We reported on the results of the possible role of alpha-cyclodextrin and hydroxytyrosol in improving defenses against SARS-CoV-2. The next step will be the administration of the compound to a larger cohort in a controlled study to confirm the reduction of the infection rate of SARS-CoV-2 in the treated subjects.
Identifiants
pubmed: 33170176
doi: 10.23750/abm.v91i13-S.10817
pmc: PMC8023124
doi:
Substances chimiques
Antiviral Agents
0
Oral Sprays
0
alpha-Cyclodextrins
0
3,4-dihydroxyphenylethanol
10597-60-1
Phenylethyl Alcohol
ML9LGA7468
alpha-cyclodextrin
Z1LH97KTRM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2020022Références
Proc Natl Acad Sci U S A. 2016 Dec 6;113(49):14025-14030
pubmed: 27872310
Biochim Biophys Acta. 2014 Jun;1838(6):1638-56
pubmed: 24440426
J Biotechnol. 2020 Feb 10;309:29-33
pubmed: 31884046
J Med Virol. 2021 Jan;93(1):250-256
pubmed: 32592501
Acta Biomed. 2020 Nov 09;91(13-S):e2020009
pubmed: 33170175
Biomedicines. 2018 Jan 26;6(1):
pubmed: 29373553
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
J Agric Food Chem. 2008 Apr 23;56(8):2630-6
pubmed: 18380465
Int J Biol Macromol. 2020 Dec 1;164:1693-1703
pubmed: 32745548
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Antiviral Res. 2009 Jul;83(1):35-44
pubmed: 19501255